This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7b-5p | AIFM1 | 0.06 | 0.7814 | -0.33 | 0.06746 | miRNATAP | -0.19 | 0.00202 | NA | |
2 | hsa-let-7i-5p | AIFM1 | 0.8 | 3.0E-5 | -0.33 | 0.06746 | miRNATAP | -0.23 | 0.00049 | NA | |
3 | hsa-miR-125a-5p | AIFM1 | -0.88 | 0.00021 | -0.33 | 0.06746 | miRanda | -0.12 | 0.02693 | NA | |
4 | hsa-miR-125b-5p | AIFM1 | -0.51 | 0.13327 | -0.33 | 0.06746 | miRNATAP | -0.22 | 0 | NA | |
5 | hsa-miR-143-5p | AIFM1 | -0.45 | 0.12536 | -0.33 | 0.06746 | miRNATAP | -0.11 | 0.01208 | NA | |
6 | hsa-miR-145-5p | AIFM1 | -1.75 | 2.0E-5 | -0.33 | 0.06746 | miRNATAP | -0.1 | 0.00169 | 20332243 | Artificial overexpression of miR145 by using adenoviral vectors in prostate cancer PC-3 and DU145 cells significantly downregulated BNIP3 together with the upregulation of AIF reduced cell growth and increased cell death |
7 | hsa-miR-199a-5p | AIFM1 | 0.37 | 0.23266 | -0.33 | 0.06746 | miRanda | -0.21 | 0 | NA | |
8 | hsa-miR-10a-5p | AKT2 | -0.47 | 0.1488 | -0.01 | 0.9227 | mirMAP | -0.07 | 0.03038 | NA | |
9 | hsa-miR-21-5p | AKT2 | 1.75 | 0 | -0.01 | 0.9227 | miRNAWalker2 validate | -0.15 | 0.00352 | NA | |
10 | hsa-miR-29a-3p | AKT2 | -0.11 | 0.61501 | -0.01 | 0.9227 | MirTarget | -0.1 | 0.02733 | 24076586 | Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
11 | hsa-miR-29b-3p | AKT2 | -0.23 | 0.36746 | -0.01 | 0.9227 | MirTarget | -0.14 | 0.00022 | 26512921; 26564501; 24076586 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3;The expression of miR-29b was significantly upregualted by cisplatin treatmentwhile its target gene AKT2 was downregulated;Furthermore a feed-back loop comprising of c-Myc miR-29 family and Akt2 were found in myeloid leukemogenesis |
12 | hsa-miR-29c-3p | AKT2 | -1.62 | 0 | -0.01 | 0.9227 | MirTarget | -0.07 | 0.02525 | NA | |
13 | hsa-miR-502-5p | AKT2 | -0.26 | 0.52045 | -0.01 | 0.9227 | mirMAP | -0.09 | 0.00016 | NA | |
14 | hsa-miR-106b-5p | AKT3 | 1.71 | 0 | -0.75 | 0.06936 | miRNATAP | -0.37 | 7.0E-5 | NA | |
15 | hsa-miR-107 | AKT3 | 0.9 | 5.0E-5 | -0.75 | 0.06936 | PITA; miRanda | -0.6 | 0 | NA | |
16 | hsa-miR-15a-5p | AKT3 | 1.04 | 0 | -0.75 | 0.06936 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.27 | 0.04887 | NA | |
17 | hsa-miR-15b-5p | AKT3 | 1.62 | 0 | -0.75 | 0.06936 | miRNATAP | -0.36 | 0.00041 | NA | |
18 | hsa-miR-16-5p | AKT3 | 1.01 | 1.0E-5 | -0.75 | 0.06936 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.47 | 0.00031 | NA | |
19 | hsa-miR-17-3p | AKT3 | 1.31 | 0 | -0.75 | 0.06936 | miRNATAP | -0.52 | 0 | NA | |
20 | hsa-miR-17-5p | AKT3 | 1.66 | 0 | -0.75 | 0.06936 | TargetScan; miRNATAP | -0.28 | 0.0027 | NA | |
21 | hsa-miR-20a-5p | AKT3 | 1.45 | 0 | -0.75 | 0.06936 | miRNATAP | -0.25 | 0.01166 | NA | |
22 | hsa-miR-29a-3p | AKT3 | -0.11 | 0.61501 | -0.75 | 0.06936 | miRNATAP | -0.41 | 0.00212 | NA | |
23 | hsa-miR-29b-3p | AKT3 | -0.23 | 0.36746 | -0.75 | 0.06936 | miRNATAP | -0.34 | 0.00361 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
24 | hsa-miR-3065-5p | AKT3 | -0.24 | 0.63312 | -0.75 | 0.06936 | mirMAP | -0.13 | 0.03593 | NA | |
25 | hsa-miR-32-3p | AKT3 | 0.58 | 0.11837 | -0.75 | 0.06936 | mirMAP | -0.32 | 0.00023 | NA | |
26 | hsa-miR-320b | AKT3 | 1.11 | 0.0005 | -0.75 | 0.06936 | PITA; miRanda; miRNATAP | -0.26 | 0.0039 | NA | |
27 | hsa-miR-335-3p | AKT3 | 2.52 | 0 | -0.75 | 0.06936 | mirMAP | -0.22 | 0.00074 | NA | |
28 | hsa-miR-33a-3p | AKT3 | 0.35 | 0.32171 | -0.75 | 0.06936 | mirMAP | -0.38 | 2.0E-5 | NA | |
29 | hsa-miR-362-3p | AKT3 | -0.03 | 0.91378 | -0.75 | 0.06936 | miRanda | -0.38 | 4.0E-5 | NA | |
30 | hsa-miR-362-5p | AKT3 | -0.35 | 0.35491 | -0.75 | 0.06936 | PITA; TargetScan; miRNATAP | -0.23 | 0.00253 | NA | |
31 | hsa-miR-3662 | AKT3 | 1.83 | 0.0054 | -0.75 | 0.06936 | mirMAP | -0.15 | 0.01121 | NA | |
32 | hsa-miR-421 | AKT3 | 1.81 | 0 | -0.75 | 0.06936 | miRanda; mirMAP | -0.21 | 0.01124 | NA | |
33 | hsa-miR-424-5p | AKT3 | 1.09 | 0.00042 | -0.75 | 0.06936 | miRNATAP | -0.23 | 0.01426 | 26315541 | Silencing Akt3 and E2F3 by siRNA pheno-copied the effect of ectopic miR-424 on HCC growth; Whereas overexpression of Akt3 and E2F3 attenuated the effect of miR-424 on HCC growth |
34 | hsa-miR-501-3p | AKT3 | 0.73 | 0.02704 | -0.75 | 0.06936 | miRNATAP | -0.39 | 1.0E-5 | NA | |
35 | hsa-miR-502-3p | AKT3 | -0.16 | 0.55747 | -0.75 | 0.06936 | miRNATAP | -0.5 | 0 | NA | |
36 | hsa-miR-505-3p | AKT3 | 0.83 | 0.00112 | -0.75 | 0.06936 | mirMAP | -0.35 | 0.00235 | 22051041 | We also find that Akt3 correlate inversely with miR-505 modulates drug sensitivity in MCF7-ADR |
37 | hsa-miR-548v | AKT3 | -0.16 | 0.70867 | -0.75 | 0.06936 | miRNATAP | -0.27 | 0.00031 | NA | |
38 | hsa-miR-577 | AKT3 | 0.91 | 0.22561 | -0.75 | 0.06936 | mirMAP | -0.23 | 0 | NA | |
39 | hsa-miR-616-5p | AKT3 | 0.83 | 0.03478 | -0.75 | 0.06936 | mirMAP | -0.27 | 0.00041 | NA | |
40 | hsa-miR-93-5p | AKT3 | 1.75 | 0 | -0.75 | 0.06936 | miRNATAP | -0.2 | 0.03321 | NA | |
41 | hsa-miR-23a-3p | APAF1 | 1.11 | 0 | 0.3 | 0.22769 | miRNATAP | -0.49 | 0 | 24992592; 24249161 | Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed |
42 | hsa-miR-23b-3p | APAF1 | -0.29 | 0.18665 | 0.3 | 0.22769 | miRNATAP | -0.54 | 0 | NA | |
43 | hsa-miR-27a-3p | APAF1 | 1.3 | 0 | 0.3 | 0.22769 | miRNATAP | -0.39 | 0 | NA | |
44 | hsa-miR-27b-3p | APAF1 | 0.08 | 0.72527 | 0.3 | 0.22769 | miRNATAP | -0.48 | 0 | NA | |
45 | hsa-miR-708-3p | APAF1 | 0.62 | 0.27536 | 0.3 | 0.22769 | mirMAP | -0.24 | 0 | NA | |
46 | hsa-miR-944 | APAF1 | 3.33 | 0.01778 | 0.3 | 0.22769 | miRNATAP | -0.13 | 0 | NA | |
47 | hsa-miR-125a-3p | ATM | 1.2 | 0.00164 | -0.39 | 0.08341 | miRanda | -0.13 | 0.00188 | NA | |
48 | hsa-miR-203a-3p | ATM | 1.45 | 0.03941 | -0.39 | 0.08341 | MirTarget | -0.14 | 0 | 24145123; 27542403 | miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression |
49 | hsa-miR-324-5p | ATM | 1.09 | 3.0E-5 | -0.39 | 0.08341 | miRanda | -0.12 | 0.04523 | NA | |
50 | hsa-miR-34c-5p | ATM | 2.21 | 0.00038 | -0.39 | 0.08341 | miRanda | -0.06 | 0.03026 | NA | |
51 | hsa-miR-590-5p | ATM | 1.04 | 0.00027 | -0.39 | 0.08341 | mirMAP | -0.17 | 0.00247 | NA | |
52 | hsa-miR-944 | ATM | 3.33 | 0.01778 | -0.39 | 0.08341 | mirMAP | -0.07 | 0 | NA | |
53 | hsa-miR-30a-5p | BAX | -1.72 | 0 | 1.23 | 0 | miRNAWalker2 validate | -0.15 | 0.00018 | NA | |
54 | hsa-miR-365a-3p | BAX | -0.89 | 0.00255 | 1.23 | 0 | miRNAWalker2 validate | -0.19 | 6.0E-5 | 24216611 | MiR 365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro apoptotic regulator BAX |
55 | hsa-miR-15b-3p | BCL2 | 1.76 | 0 | -1.09 | 0.00317 | mirMAP | -0.24 | 0.00334 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
56 | hsa-miR-16-2-3p | BCL2 | 1.8 | 0 | -1.09 | 0.00317 | mirMAP | -0.26 | 0.0023 | NA | |
57 | hsa-miR-17-5p | BCL2 | 1.66 | 0 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase | -0.2 | 0.01676 | 25435430 | Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2 |
58 | hsa-miR-181b-5p | BCL2 | 1.64 | 0 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase | -0.22 | 0.01271 | 25524579 | Moreover we also found miR-181 reduction was associated with increased Bcl-2 levels and miR-181 was further suggested to exert its pro-apoptotic function mainly through targeting Bcl-2 expression |
59 | hsa-miR-192-5p | BCL2 | 0.08 | 0.94106 | -1.09 | 0.00317 | miRNAWalker2 validate | -0.07 | 0.00226 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
60 | hsa-miR-196b-5p | BCL2 | 5.59 | 0 | -1.09 | 0.00317 | miRNAWalker2 validate | -0.1 | 0.01463 | NA | |
61 | hsa-miR-200a-5p | BCL2 | 1.5 | 0.00264 | -1.09 | 0.00317 | mirMAP | -0.21 | 5.0E-5 | NA | |
62 | hsa-miR-200b-3p | BCL2 | 0.97 | 0.0595 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP | -0.18 | 0.00034 | NA | |
63 | hsa-miR-200b-5p | BCL2 | 0.97 | 0.05305 | -1.09 | 0.00317 | mirMAP | -0.21 | 0.00019 | NA | |
64 | hsa-miR-200c-3p | BCL2 | 1.28 | 0.0037 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.23 | 0.00013 | NA | |
65 | hsa-miR-20a-3p | BCL2 | 1.14 | 0.00045 | -1.09 | 0.00317 | mirMAP | -0.22 | 0.00669 | NA | |
66 | hsa-miR-21-5p | BCL2 | 1.75 | 0 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase | -0.57 | 2.0E-5 | 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 | BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
67 | hsa-miR-215-5p | BCL2 | 0.72 | 0.57378 | -1.09 | 0.00317 | miRNAWalker2 validate | -0.07 | 0.00067 | NA | |
68 | hsa-miR-24-2-5p | BCL2 | 1.25 | 0 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase | -0.22 | 0.0345 | NA | |
69 | hsa-miR-29a-5p | BCL2 | 0.59 | 0.02301 | -1.09 | 0.00317 | mirMAP | -0.28 | 0.00622 | 20041405 | Subsequent investigation characterized two antiapoptotic molecules Bcl-2 and Mcl-1 as direct targets of miR-29; Furthermore silencing of Bcl-2 and Mcl-1 phenocopied the proapoptotic effect of miR-29 whereas overexpression of these proteins attenuated the effect of miR-29 |
70 | hsa-miR-3065-5p | BCL2 | -0.24 | 0.63312 | -1.09 | 0.00317 | mirMAP | -0.13 | 0.01807 | NA | |
71 | hsa-miR-335-3p | BCL2 | 2.52 | 0 | -1.09 | 0.00317 | mirMAP | -0.17 | 0.00598 | NA | |
72 | hsa-miR-338-5p | BCL2 | -1.2 | 0.01003 | -1.09 | 0.00317 | PITA | -0.12 | 0.0383 | NA | |
73 | hsa-miR-34a-5p | BCL2 | 0.79 | 0.00024 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.02855 | 24565525; 23155233; 24444609; 20687223; 22623155; 24988056; 18803879; 19714243; 25053345; 20433755; 21399894; 22964582; 23862748 | In vitro and in vivo experiments showed that miR-34a and DOX can be efficiently encapsulated into HA-CS NPs and delivered into tumor cells or tumor tissues and enhance anti-tumor effects of DOX by suppressing the expression of non-pump resistance and anti-apoptosis proto-oncogene Bcl-2;The miR-34a expression levels in cells after irradiation at 30 and 60 Gy were 0.17- and 18.7-times the BCL2 and caspase-9 expression levels respectively;Functional analyses further indicate that restoration of miR-34a inhibits B cell lymphoma-2 Bcl-2 protein expression to withdraw the survival advantage of these resistant NSCLC cells;Thus in PC3PR cells reduced expression of miR-34a confers paclitaxel resistance via up-regulating SIRT1 and Bcl2 expression; MiR-34a and its downstream targets SIRT1 and Bcl2 play important roles in the development of paclitaxel resistance all of which can be useful biomarkers and promising therapeutic targets for the drug resistance in hormone-refractory prostate cancer;MiR 34a inhibits proliferation and migration of breast cancer through down regulation of Bcl 2 and SIRT1; In this study we aimed to determine the effect of miR-34a on the growth of breast cancer and to investigate whether its effect is achieved by targeting Bcl-2 and SIRT1; Bcl-2 and SIRT1 as the targets of miR-34a were found to be in reverse correlation with ectopic expression of miR-34a;Target analysis indicated that micro RNA miR-34a directly regulates Bcl-2 and miR-34a overexpression decreased Bcl-2 protein level in gastric cancer cells; We also found that luteolin upregulates miR-34a expression and downregulates Bcl-2 expression; Based on these results we can draw the conclusion that luteolin partly decreases Bcl-2 expression through upregulating miR-34a expression;miR-34 targets Notch HMGA2 and Bcl-2 genes involved in the self-renewal and survival of cancer stem cells; Human gastric cancer cells were transfected with miR-34 mimics or infected with the lentiviral miR-34-MIF expression system and validated by miR-34 reporter assay using Bcl-2 3'UTR reporter; Human gastric cancer Kato III cells with miR-34 restoration reduced the expression of target genes Bcl-2 Notch and HMGA2; Bcl-2 3'UTR reporter assay showed that the transfected miR-34s were functional and confirmed that Bcl-2 is a direct target of miR-34; The mechanism of miR-34-mediated suppression of self-renewal appears to be related to the direct modulation of downstream targets Bcl-2 Notch and HMGA2 indicating that miR-34 may be involved in gastric cancer stem cell self-renewal/differentiation decision-making;Among the target proteins regulated by miR-34 are Notch pathway proteins and Bcl-2 suggesting the possibility of a role for miR-34 in the maintenance and survival of cancer stem cells; Our data support the view that miR-34 may be involved in pancreatic cancer stem cell self-renewal potentially via the direct modulation of downstream targets Bcl-2 and Notch implying that miR-34 may play an important role in pancreatic cancer stem cell self-renewal and/or cell fate determination;Manipulating miR-34a in prostate cancer cells confirms that this miRNA regulates BCL-2 and may in part regulate response to docetaxel;For instance miR-34a up-regulation corresponded with a down-regulation of BCL2 protein; Treating Par-4-overexpressing HT29 cells with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;MicroRNA 34a targets Bcl 2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment; HCC tissues with lower miR-34a expression displayed higher expression of Bcl-2 protein than those with high expression of miR-34a; therefore an inverse correlation is evident between the miR-34a level and Bcl-2 expression; Bioinformatics and luciferase reporter assays revealed that miR-34a binds the 3'-UTR of the Bcl-2 mRNA and represses its translation; Western blotting analysis and qRT-PCR confirmed that Bcl-2 is inhibited by miR-34a overexpression; Functional analyses indicated that the restoration of miR-34a reduced cell viability promoted cell apoptosis and potentiated sorafenib-induced apoptosis and toxicity in HCC cell lines by inhibiting Bcl-2 expression |
74 | hsa-miR-375 | BCL2 | -2.95 | 0.0057 | -1.09 | 0.00317 | miRNAWalker2 validate | -0.05 | 0.03382 | 26381132; 26697569; 25613180 | The levels of miR-375 Bax and Bcl-2 protein expression in treated cells were determined by Western blot and RT-PCR; Moreover compared to control group the expression of Bcl-2 and miR-375 decreases with formononetin in the U2OS cells while Bax increases;Exosome Carried microRNA 375 Inhibits Cell Progression and Dissemination via Bcl 2 Blocking in Colon Cancer; RT-PCR for Bcl-2 expression showed that Bcl-2 is down-regulated for miR-375 inhibitor and up-regulated for the miR-375 mimic a result confirmed by Western blotting; The present study brings to the forefront new data that suggest miR-375 as a new player in controlling the pathways responsible for inhibiting the natural history of CRC tumor cells via the Bcl-2 pathway;mRNA levels of ERα Bcl-2 and miR-375 were quantified using real-time polymerase chain reaction; After treatment with biochanin A ERα miR-375 and Bcl-2 expression was significantly upregulated |
75 | hsa-miR-429 | BCL2 | 1.4 | 0.009 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase; PITA; mirMAP | -0.2 | 3.0E-5 | 23999873; 26513239; 26511969 | MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation |
76 | hsa-miR-455-5p | BCL2 | 1.2 | 7.0E-5 | -1.09 | 0.00317 | mirMAP | -0.35 | 4.0E-5 | NA | |
77 | hsa-miR-577 | BCL2 | 0.91 | 0.22561 | -1.09 | 0.00317 | PITA | -0.1 | 0.00537 | NA | |
78 | hsa-miR-590-3p | BCL2 | 1.12 | 0.00016 | -1.09 | 0.00317 | miRanda; mirMAP | -0.2 | 0.02525 | NA | |
79 | hsa-miR-590-5p | BCL2 | 1.04 | 0.00027 | -1.09 | 0.00317 | miRanda | -0.2 | 0.03472 | NA | |
80 | hsa-miR-7-1-3p | BCL2 | 0.71 | 0.04123 | -1.09 | 0.00317 | mirMAP | -0.19 | 0.0132 | NA | |
81 | hsa-miR-7-5p | BCL2 | 1.64 | 0.01244 | -1.09 | 0.00317 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.14 | 0.00068 | 26464649; 25862909; 21750649 | Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions |
82 | hsa-let-7b-5p | BCL2L1 | 0.06 | 0.7814 | 0.21 | 0.39578 | miRNATAP | -0.31 | 0.00027 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
83 | hsa-let-7c-5p | BCL2L1 | -0.5 | 0.20685 | 0.21 | 0.39578 | miRNAWalker2 validate; miRTarBase | -0.2 | 1.0E-5 | 20347499 | Over-expression of let-7c or let-7g led to a clear decrease of Bcl-xL expression in Huh7 and HepG2 cell lines; Reporter assays revealed direct post-transcriptional regulation involving let-7c or let-7g and the 3'-untranslated region of bcl-xl mRNA |
84 | hsa-let-7i-5p | BCL2L1 | 0.8 | 3.0E-5 | 0.21 | 0.39578 | miRNATAP | -0.21 | 0.02883 | NA | |
85 | hsa-miR-133a-3p | BCL2L1 | -3.07 | 0 | 0.21 | 0.39578 | miRNAWalker2 validate | -0.08 | 0.00328 | 23756231 | Furthermore bioinformatic prediction and experimental validation were applied to identify target genes of miR-133a and the results revealed that the anti-tumor effect of miR-133a was probably due to targeting and repressing of Bcl-xL and Mcl-1 expression |
86 | hsa-miR-149-5p | BCL2L1 | 0.71 | 0.29685 | 0.21 | 0.39578 | mirMAP | -0.17 | 0 | NA | |
87 | hsa-miR-214-3p | BCL2L1 | 1.01 | 0.00625 | 0.21 | 0.39578 | mirMAP | -0.13 | 0.00824 | NA | |
88 | hsa-miR-23b-3p | BCL2L1 | -0.29 | 0.18665 | 0.21 | 0.39578 | miRNAWalker2 validate | -0.39 | 0 | NA | |
89 | hsa-miR-342-3p | BCL2L1 | 0.32 | 0.26915 | 0.21 | 0.39578 | PITA; miRanda; miRNATAP | -0.15 | 0.01448 | NA | |
90 | hsa-miR-624-5p | BIRC2 | 1.03 | 0.00109 | 0.15 | 0.34408 | MirTarget | -0.08 | 0.03344 | NA | |
91 | hsa-miR-24-2-5p | BIRC3 | 1.25 | 0 | -0.43 | 0.44493 | MirTarget | -0.4 | 0.01021 | NA | |
92 | hsa-miR-28-3p | BIRC3 | -0.73 | 0.00035 | -0.43 | 0.44493 | MirTarget | -0.4 | 0.04567 | NA | |
93 | hsa-miR-369-3p | BIRC3 | 0.32 | 0.35899 | -0.43 | 0.44493 | MirTarget; miRNATAP | -0.26 | 0.02353 | NA | |
94 | hsa-miR-496 | BIRC3 | 0.57 | 0.16341 | -0.43 | 0.44493 | mirMAP | -0.24 | 0.03348 | NA | |
95 | hsa-miR-651-5p | BIRC3 | 0.67 | 0.06005 | -0.43 | 0.44493 | MirTarget | -0.25 | 0.02779 | NA | |
96 | hsa-miR-491-5p | CAPN1 | -0.69 | 0.03136 | 0.47 | 0.04786 | miRanda | -0.18 | 0.0005 | NA | |
97 | hsa-miR-107 | CAPN2 | 0.9 | 5.0E-5 | -0.59 | 0.00617 | miRanda | -0.2 | 0.00395 | NA | |
98 | hsa-miR-20a-3p | CAPN2 | 1.14 | 0.00045 | -0.59 | 0.00617 | MirTarget | -0.11 | 0.01449 | NA | |
99 | hsa-miR-320a | CAPN2 | 0.59 | 0.0119 | -0.59 | 0.00617 | miRanda | -0.26 | 6.0E-5 | NA | |
100 | hsa-miR-320b | CAPN2 | 1.11 | 0.0005 | -0.59 | 0.00617 | miRanda | -0.16 | 0.00048 | NA | |
101 | hsa-miR-421 | CAPN2 | 1.81 | 0 | -0.59 | 0.00617 | miRanda | -0.18 | 2.0E-5 | NA | |
102 | hsa-miR-7-5p | CAPN2 | 1.64 | 0.01244 | -0.59 | 0.00617 | miRNAWalker2 validate | -0.06 | 0.0095 | NA | |
103 | hsa-miR-125b-5p | CASP10 | -0.51 | 0.13327 | 0.32 | 0.44988 | mirMAP | -0.45 | 0 | NA | |
104 | hsa-miR-129-5p | CASP10 | -2.57 | 0 | 0.32 | 0.44988 | mirMAP | -0.15 | 0.0057 | NA | |
105 | hsa-miR-145-3p | CASP10 | -1.65 | 2.0E-5 | 0.32 | 0.44988 | mirMAP | -0.22 | 0.00525 | NA | |
106 | hsa-miR-145-5p | CASP10 | -1.75 | 2.0E-5 | 0.32 | 0.44988 | mirMAP | -0.21 | 0.00404 | NA | |
107 | hsa-miR-34c-3p | CASP10 | 2.25 | 9.0E-5 | 0.32 | 0.44988 | mirMAP | -0.32 | 0 | NA | |
108 | hsa-miR-374a-3p | CASP10 | 0.04 | 0.85148 | 0.32 | 0.44988 | mirMAP | -0.31 | 0.02523 | NA | |
109 | hsa-miR-452-5p | CASP10 | 2.09 | 0.00026 | 0.32 | 0.44988 | mirMAP | -0.28 | 0 | NA | |
110 | hsa-miR-744-3p | CASP10 | 1.4 | 0.00097 | 0.32 | 0.44988 | mirMAP | -0.35 | 0 | NA | |
111 | hsa-let-7b-5p | CASP3 | 0.06 | 0.7814 | 0.56 | 0.00075 | MirTarget; miRNATAP | -0.11 | 0.04898 | NA | |
112 | hsa-let-7c-5p | CASP3 | -0.5 | 0.20685 | 0.56 | 0.00075 | MirTarget | -0.09 | 0.00144 | NA | |
113 | hsa-miR-129-5p | CASP3 | -2.57 | 0 | 0.56 | 0.00075 | mirMAP | -0.07 | 0.0012 | 23744359 | The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3 |
114 | hsa-miR-193b-5p | CASP3 | 0.61 | 0.13924 | 0.56 | 0.00075 | MirTarget | -0.09 | 0.0012 | NA | |
115 | hsa-miR-369-3p | CASP6 | 0.32 | 0.35899 | 0.39 | 0.09276 | MirTarget | -0.11 | 0.01531 | NA | |
116 | hsa-miR-129-5p | CASP7 | -2.57 | 0 | 0.22 | 0.30127 | miRanda | -0.06 | 0.03003 | NA | |
117 | hsa-miR-23b-3p | CASP7 | -0.29 | 0.18665 | 0.22 | 0.30127 | MirTarget | -0.19 | 0.00671 | NA | |
118 | hsa-miR-9-3p | CASP7 | 0.33 | 0.54111 | 0.22 | 0.30127 | MirTarget | -0.1 | 0.00051 | NA | |
119 | hsa-miR-129-5p | CASP8 | -2.57 | 0 | 1.08 | 0 | miRanda | -0.14 | 0 | NA | |
120 | hsa-miR-143-3p | CASP8 | -0.66 | 0.04832 | 1.08 | 0 | MirTarget | -0.19 | 3.0E-5 | NA | |
121 | hsa-miR-20b-5p | CASP8 | -0.75 | 0.1377 | 1.08 | 0 | MirTarget | -0.06 | 0.04587 | NA | |
122 | hsa-miR-193b-3p | CASP9 | 0.28 | 0.45126 | -0.31 | 0.11004 | miRNAWalker2 validate | -0.17 | 0 | NA | |
123 | hsa-miR-103a-2-5p | CFLAR | 0.81 | 0.01999 | 0.07 | 0.73819 | mirMAP | -0.11 | 0.01177 | NA | |
124 | hsa-miR-130a-3p | CFLAR | 0.15 | 0.63374 | 0.07 | 0.73819 | mirMAP | -0.14 | 0.00421 | NA | |
125 | hsa-miR-130b-3p | CFLAR | 1.33 | 5.0E-5 | 0.07 | 0.73819 | mirMAP | -0.21 | 0 | NA | |
126 | hsa-miR-15b-5p | CFLAR | 1.62 | 0 | 0.07 | 0.73819 | mirMAP | -0.22 | 4.0E-5 | NA | |
127 | hsa-miR-16-5p | CFLAR | 1.01 | 1.0E-5 | 0.07 | 0.73819 | mirMAP | -0.17 | 0.01274 | NA | |
128 | hsa-miR-224-3p | CFLAR | 1.52 | 0.0065 | 0.07 | 0.73819 | mirMAP | -0.09 | 0.00145 | NA | |
129 | hsa-miR-224-5p | CFLAR | 2.76 | 0.00011 | 0.07 | 0.73819 | MirTarget | -0.06 | 0.00246 | NA | |
130 | hsa-miR-301a-3p | CFLAR | 1.45 | 1.0E-5 | 0.07 | 0.73819 | mirMAP | -0.2 | 1.0E-5 | NA | |
131 | hsa-miR-320b | CFLAR | 1.11 | 0.0005 | 0.07 | 0.73819 | miRanda | -0.11 | 0.02613 | NA | |
132 | hsa-miR-320c | CFLAR | 0.46 | 0.24061 | 0.07 | 0.73819 | miRanda | -0.11 | 0.01943 | NA | |
133 | hsa-miR-34c-5p | CFLAR | 2.21 | 0.00038 | 0.07 | 0.73819 | miRanda | -0.09 | 0.00022 | NA | |
134 | hsa-miR-455-5p | CFLAR | 1.2 | 7.0E-5 | 0.07 | 0.73819 | miRanda | -0.1 | 0.04815 | NA | |
135 | hsa-miR-484 | CFLAR | 0.71 | 0.00234 | 0.07 | 0.73819 | mirMAP | -0.16 | 0.0119 | NA | |
136 | hsa-miR-708-5p | CFLAR | 1.42 | 0.01096 | 0.07 | 0.73819 | mirMAP | -0.1 | 0.00027 | NA | |
137 | hsa-miR-9-5p | CFLAR | -0.2 | 0.76147 | 0.07 | 0.73819 | mirMAP | -0.13 | 0 | NA | |
138 | hsa-miR-152-3p | CHUK | 0.44 | 0.1617 | -0.11 | 0.43611 | MirTarget | -0.17 | 0 | NA | |
139 | hsa-miR-195-5p | CHUK | -0.91 | 0.00151 | -0.11 | 0.43611 | miRNAWalker2 validate; MirTarget | -0.13 | 0.00012 | NA | |
140 | hsa-miR-23a-3p | CHUK | 1.11 | 0 | -0.11 | 0.43611 | MirTarget | -0.17 | 0.00056 | NA | |
141 | hsa-miR-23b-3p | CHUK | -0.29 | 0.18665 | -0.11 | 0.43611 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.19 | 6.0E-5 | NA | |
142 | hsa-miR-342-3p | CHUK | 0.32 | 0.26915 | -0.11 | 0.43611 | miRanda | -0.19 | 0 | NA | |
143 | hsa-miR-376c-3p | CHUK | -0.02 | 0.95345 | -0.11 | 0.43611 | MirTarget | -0.08 | 0.00918 | NA | |
144 | hsa-miR-497-5p | CHUK | -0.8 | 0.0036 | -0.11 | 0.43611 | MirTarget | -0.11 | 0.00273 | NA | |
145 | hsa-miR-655-3p | CHUK | 0.3 | 0.39642 | -0.11 | 0.43611 | MirTarget | -0.08 | 0.00609 | NA | |
146 | hsa-miR-15b-3p | CSF2RB | 1.76 | 0 | -0.2 | 0.59657 | mirMAP | -0.31 | 0.00012 | NA | |
147 | hsa-miR-19a-3p | CSF2RB | 1.27 | 0.00011 | -0.2 | 0.59657 | MirTarget | -0.18 | 0.02841 | NA | |
148 | hsa-miR-30b-3p | CSF2RB | -0.27 | 0.40085 | -0.2 | 0.59657 | MirTarget | -0.25 | 0.00393 | NA | |
149 | hsa-miR-452-3p | CSF2RB | 2.2 | 0.00185 | -0.2 | 0.59657 | mirMAP | -0.13 | 0.00156 | NA | |
150 | hsa-miR-455-5p | CSF2RB | 1.2 | 7.0E-5 | -0.2 | 0.59657 | miRanda | -0.2 | 0.02508 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 48 | 1929 | 1.224e-33 | 3.412e-30 |
2 | INTRACELLULAR SIGNAL TRANSDUCTION | 45 | 1572 | 1.466e-33 | 3.412e-30 |
3 | REGULATION OF CELL DEATH | 41 | 1472 | 1.985e-29 | 3.079e-26 |
4 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 44 | 1848 | 3.152e-29 | 3.667e-26 |
5 | CELL DEATH | 36 | 1001 | 4.464e-29 | 4.155e-26 |
6 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 19 | 99 | 6.974e-29 | 4.636e-26 |
7 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 22 | 179 | 6.502e-29 | 4.636e-26 |
8 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 23 | 233 | 5.618e-28 | 3.268e-25 |
9 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 40 | 1492 | 6.323e-28 | 3.269e-25 |
10 | APOPTOTIC SIGNALING PATHWAY | 24 | 289 | 2.231e-27 | 1.038e-24 |
11 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 42 | 1791 | 2.666e-27 | 1.128e-24 |
12 | IMMUNE SYSTEM PROCESS | 43 | 1984 | 1.021e-26 | 3.958e-24 |
13 | POSITIVE REGULATION OF CELL COMMUNICATION | 39 | 1532 | 2.978e-26 | 1.066e-23 |
14 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 40 | 1656 | 3.389e-26 | 1.126e-23 |
15 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 32 | 876 | 1.092e-25 | 3.389e-23 |
16 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 21 | 213 | 1.665e-25 | 4.843e-23 |
17 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 17 | 95 | 2.609e-25 | 7.14e-23 |
18 | ACTIVATION OF IMMUNE RESPONSE | 25 | 427 | 9.726e-25 | 2.514e-22 |
19 | NEGATIVE REGULATION OF CELL DEATH | 31 | 872 | 1.867e-24 | 4.572e-22 |
20 | RESPONSE TO CYTOKINE | 29 | 714 | 2.254e-24 | 5.245e-22 |
21 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 36 | 1381 | 3.057e-24 | 6.774e-22 |
22 | ZYMOGEN ACTIVATION | 17 | 112 | 5.246e-24 | 1.109e-21 |
23 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 13 | 39 | 1.819e-23 | 3.68e-21 |
24 | REGULATION OF IMMUNE RESPONSE | 30 | 858 | 2.172e-23 | 4.211e-21 |
25 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 10 | 13 | 2.93e-23 | 5.454e-21 |
26 | POSITIVE REGULATION OF IMMUNE RESPONSE | 26 | 563 | 3.995e-23 | 7.15e-21 |
27 | REGULATION OF IMMUNE SYSTEM PROCESS | 35 | 1403 | 7.796e-23 | 1.343e-20 |
28 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 35 | 1518 | 1.041e-21 | 1.73e-19 |
29 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 17 | 154 | 1.528e-21 | 2.451e-19 |
30 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 10 | 17 | 1.972e-21 | 3.058e-19 |
31 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 98 | 2.644e-21 | 3.969e-19 |
32 | ACTIVATION OF INNATE IMMUNE RESPONSE | 18 | 204 | 5.436e-21 | 7.904e-19 |
33 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 15 | 109 | 1.43e-20 | 2.016e-18 |
34 | PROTEIN MATURATION | 19 | 265 | 2.059e-20 | 2.781e-18 |
35 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 14 | 85 | 2.092e-20 | 2.781e-18 |
36 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 16 | 153 | 6.447e-20 | 7.969e-18 |
37 | REGULATION OF PEPTIDASE ACTIVITY | 21 | 392 | 6.508e-20 | 7.969e-18 |
38 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 10 | 22 | 6.469e-20 | 7.969e-18 |
39 | POSITIVE REGULATION OF CELL DEATH | 24 | 605 | 9.521e-20 | 1.136e-17 |
40 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 27 | 867 | 1.333e-19 | 1.55e-17 |
41 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 18 | 246 | 1.636e-19 | 1.857e-17 |
42 | REGULATION OF PROTEOLYSIS | 25 | 711 | 2.442e-19 | 2.705e-17 |
43 | POSITIVE REGULATION OF DEFENSE RESPONSE | 20 | 364 | 3.503e-19 | 3.79e-17 |
44 | RESPONSE TO NITROGEN COMPOUND | 26 | 859 | 1.555e-18 | 1.645e-16 |
45 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 23 | 606 | 1.758e-18 | 1.817e-16 |
46 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 16 | 200 | 5.077e-18 | 5.135e-16 |
47 | REGULATION OF INNATE IMMUNE RESPONSE | 19 | 357 | 5.67e-18 | 5.613e-16 |
48 | REGULATION OF RESPONSE TO STRESS | 31 | 1468 | 7.732e-18 | 7.495e-16 |
49 | RESPONSE TO ABIOTIC STIMULUS | 27 | 1024 | 9.178e-18 | 8.715e-16 |
50 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 10 | 34 | 1.271e-17 | 1.183e-15 |
51 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 18 | 323 | 2.136e-17 | 1.949e-15 |
52 | CYTOKINE MEDIATED SIGNALING PATHWAY | 20 | 452 | 2.409e-17 | 2.155e-15 |
53 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 27 | 1135 | 1.213e-16 | 1.065e-14 |
54 | POSITIVE REGULATION OF PROTEOLYSIS | 18 | 363 | 1.675e-16 | 1.417e-14 |
55 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 18 | 363 | 1.675e-16 | 1.417e-14 |
56 | REGULATION OF KINASE ACTIVITY | 23 | 776 | 3.9e-16 | 3.241e-14 |
57 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 17 | 321 | 4.375e-16 | 3.571e-14 |
58 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 14 | 171 | 5.372e-16 | 4.31e-14 |
59 | I KAPPAB KINASE NF KAPPAB SIGNALING | 11 | 70 | 5.555e-16 | 4.381e-14 |
60 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 13 | 132 | 5.684e-16 | 4.408e-14 |
61 | RESPONSE TO ENDOGENOUS STIMULUS | 29 | 1450 | 5.868e-16 | 4.476e-14 |
62 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 23 | 799 | 7.323e-16 | 5.496e-14 |
63 | PHOSPHORYLATION | 27 | 1228 | 8.577e-16 | 6.335e-14 |
64 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 16 | 279 | 1.026e-15 | 7.459e-14 |
65 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 30 | 1618 | 1.154e-15 | 8.263e-14 |
66 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 9 | 33 | 1.266e-15 | 8.792e-14 |
67 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 9 | 33 | 1.266e-15 | 8.792e-14 |
68 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 13 | 142 | 1.496e-15 | 1.024e-13 |
69 | RESPONSE TO TUMOR NECROSIS FACTOR | 15 | 233 | 1.613e-15 | 1.088e-13 |
70 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 13 | 144 | 1.8e-15 | 1.196e-13 |
71 | NEURON APOPTOTIC PROCESS | 9 | 35 | 2.305e-15 | 1.511e-13 |
72 | REGULATION OF TRANSFERASE ACTIVITY | 24 | 946 | 2.435e-15 | 1.574e-13 |
73 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 10 | 55 | 2.682e-15 | 1.709e-13 |
74 | REGULATION OF DEFENSE RESPONSE | 22 | 759 | 3.163e-15 | 1.989e-13 |
75 | REGULATION OF PROTEIN MODIFICATION PROCESS | 30 | 1710 | 5.123e-15 | 3.178e-13 |
76 | RESPONSE TO BIOTIC STIMULUS | 23 | 886 | 6.701e-15 | 4.102e-13 |
77 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 15 | 263 | 9.709e-15 | 5.867e-13 |
78 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 24 | 1036 | 1.814e-14 | 1.068e-12 |
79 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 24 | 1036 | 1.814e-14 | 1.068e-12 |
80 | POSITIVE REGULATION OF KINASE ACTIVITY | 18 | 482 | 2.303e-14 | 1.339e-12 |
81 | PROTEIN PHOSPHORYLATION | 23 | 944 | 2.574e-14 | 1.479e-12 |
82 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 14 | 228 | 2.999e-14 | 1.702e-12 |
83 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 8 | 28 | 3.435e-14 | 1.926e-12 |
84 | NEURON DEATH | 9 | 47 | 4.309e-14 | 2.387e-12 |
85 | PROTEOLYSIS | 25 | 1208 | 5.658e-14 | 3.098e-12 |
86 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 8 | 30 | 6.434e-14 | 3.481e-12 |
87 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 9 | 50 | 7.861e-14 | 4.204e-12 |
88 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 13 | 195 | 9.438e-14 | 4.99e-12 |
89 | RESPONSE TO BACTERIUM | 18 | 528 | 1.093e-13 | 5.716e-12 |
90 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 10 | 80 | 1.413e-13 | 7.306e-12 |
91 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 8 | 33 | 1.514e-13 | 7.742e-12 |
92 | FC RECEPTOR SIGNALING PATHWAY | 13 | 206 | 1.915e-13 | 9.683e-12 |
93 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 30 | 1977 | 2.408e-13 | 1.205e-11 |
94 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 17 | 505 | 7.235e-13 | 3.581e-11 |
95 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 18 | 616 | 1.477e-12 | 7.235e-11 |
96 | RESPONSE TO EXTERNAL STIMULUS | 28 | 1821 | 1.597e-12 | 7.743e-11 |
97 | T CELL RECEPTOR SIGNALING PATHWAY | 11 | 146 | 2.301e-12 | 1.104e-10 |
98 | REGULATION OF NECROTIC CELL DEATH | 7 | 26 | 2.389e-12 | 1.134e-10 |
99 | CELLULAR RESPONSE TO STRESS | 26 | 1565 | 2.421e-12 | 1.138e-10 |
100 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 16 | 470 | 3.214e-12 | 1.495e-10 |
101 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 11 | 152 | 3.583e-12 | 1.651e-10 |
102 | REGULATION OF HYDROLASE ACTIVITY | 24 | 1327 | 3.825e-12 | 1.745e-10 |
103 | RESPONSE TO PEPTIDE | 15 | 404 | 4.918e-12 | 2.221e-10 |
104 | RESPONSE TO MECHANICAL STIMULUS | 12 | 210 | 5.696e-12 | 2.548e-10 |
105 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 24 | 1360 | 6.436e-12 | 2.852e-10 |
106 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 10 | 118 | 7.564e-12 | 3.32e-10 |
107 | RESPONSE TO LIPID | 20 | 888 | 7.815e-12 | 3.399e-10 |
108 | RESPONSE TO HORMONE | 20 | 893 | 8.651e-12 | 3.727e-10 |
109 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 20 | 905 | 1.101e-11 | 4.701e-10 |
110 | EXECUTION PHASE OF APOPTOSIS | 8 | 55 | 1.252e-11 | 5.296e-10 |
111 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 14 | 365 | 1.793e-11 | 7.514e-10 |
112 | INFLAMMATORY RESPONSE | 15 | 454 | 2.569e-11 | 1.067e-09 |
113 | NEGATIVE REGULATION OF CELL COMMUNICATION | 22 | 1192 | 2.686e-11 | 1.106e-09 |
114 | HOMEOSTATIC PROCESS | 23 | 1337 | 3.421e-11 | 1.396e-09 |
115 | IMMUNE RESPONSE | 21 | 1100 | 4.61e-11 | 1.865e-09 |
116 | REGULATION OF CELL PROLIFERATION | 24 | 1496 | 4.752e-11 | 1.906e-09 |
117 | REGULATION OF NEURON DEATH | 12 | 252 | 4.805e-11 | 1.911e-09 |
118 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 12 | 264 | 8.239e-11 | 3.249e-09 |
119 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 7 | 43 | 1.118e-10 | 4.373e-09 |
120 | CELLULAR RESPONSE TO PEPTIDE | 12 | 274 | 1.266e-10 | 4.909e-09 |
121 | POSITIVE REGULATION OF GENE EXPRESSION | 25 | 1733 | 1.582e-10 | 6.082e-09 |
122 | CELLULAR GLUCOSE HOMEOSTASIS | 8 | 75 | 1.645e-10 | 6.272e-09 |
123 | REGULATION OF NECROPTOTIC PROCESS | 5 | 11 | 1.779e-10 | 6.728e-09 |
124 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 7 | 46 | 1.843e-10 | 6.907e-09 |
125 | RESPONSE TO INTERLEUKIN 1 | 9 | 115 | 1.856e-10 | 6.907e-09 |
126 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 7 | 49 | 2.934e-10 | 1.083e-08 |
127 | NIK NF KAPPAB SIGNALING | 8 | 83 | 3.763e-10 | 1.379e-08 |
128 | CELLULAR RESPONSE TO HORMONE STIMULUS | 15 | 552 | 3.92e-10 | 1.425e-08 |
129 | NECROTIC CELL DEATH | 6 | 28 | 4.378e-10 | 1.579e-08 |
130 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 5 | 13 | 4.929e-10 | 1.764e-08 |
131 | RESPONSE TO WOUNDING | 15 | 563 | 5.144e-10 | 1.827e-08 |
132 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 19 | 1008 | 6.001e-10 | 2.115e-08 |
133 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 8 | 88 | 6.051e-10 | 2.117e-08 |
134 | REGULATION OF NEURON APOPTOTIC PROCESS | 10 | 192 | 9.43e-10 | 3.274e-08 |
135 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 18 | 917 | 9.902e-10 | 3.413e-08 |
136 | T CELL APOPTOTIC PROCESS | 5 | 15 | 1.144e-09 | 3.914e-08 |
137 | T CELL HOMEOSTASIS | 6 | 34 | 1.538e-09 | 5.225e-08 |
138 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 19 | 1079 | 1.861e-09 | 6.275e-08 |
139 | REGULATION OF CATABOLIC PROCESS | 16 | 731 | 2.149e-09 | 7.147e-08 |
140 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 8 | 103 | 2.15e-09 | 7.147e-08 |
141 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 2.345e-09 | 7.738e-08 |
142 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 8 | 106 | 2.706e-09 | 8.866e-08 |
143 | POSITIVE REGULATION OF NEURON DEATH | 7 | 67 | 2.831e-09 | 9.21e-08 |
144 | LYMPHOCYTE APOPTOTIC PROCESS | 5 | 18 | 3.238e-09 | 1.046e-07 |
145 | CHEMICAL HOMEOSTASIS | 17 | 874 | 3.65e-09 | 1.171e-07 |
146 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 7 | 71 | 4.283e-09 | 1.365e-07 |
147 | WOUND HEALING | 13 | 470 | 5.467e-09 | 1.73e-07 |
148 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 7 | 74 | 5.749e-09 | 1.807e-07 |
149 | RESPONSE TO INORGANIC SUBSTANCE | 13 | 479 | 6.856e-09 | 2.141e-07 |
150 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 7.262e-09 | 2.253e-07 |
151 | NECROPTOTIC PROCESS | 5 | 21 | 7.631e-09 | 2.351e-07 |
152 | RESPONSE TO TOXIC SUBSTANCE | 10 | 241 | 8.443e-09 | 2.585e-07 |
153 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 6 | 47 | 1.186e-08 | 3.608e-07 |
154 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 23 | 1805 | 1.21e-08 | 3.655e-07 |
155 | LEUKOCYTE APOPTOTIC PROCESS | 5 | 23 | 1.255e-08 | 3.768e-07 |
156 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 5 | 24 | 1.581e-08 | 4.717e-07 |
157 | DEFENSE RESPONSE | 19 | 1231 | 1.601e-08 | 4.745e-07 |
158 | LYMPHOCYTE HOMEOSTASIS | 6 | 50 | 1.742e-08 | 5.13e-07 |
159 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 1.969e-08 | 5.733e-07 |
160 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 1.972e-08 | 5.733e-07 |
161 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 10 | 272 | 2.665e-08 | 7.703e-07 |
162 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 17 | 1004 | 2.842e-08 | 8.162e-07 |
163 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 7 | 95 | 3.337e-08 | 9.527e-07 |
164 | PEPTIDYL SERINE MODIFICATION | 8 | 148 | 3.777e-08 | 1.071e-06 |
165 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 11 | 370 | 4.471e-08 | 1.261e-06 |
166 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 6 | 59 | 4.822e-08 | 1.352e-06 |
167 | CELL ACTIVATION | 13 | 568 | 5.116e-08 | 1.425e-06 |
168 | LEUKOCYTE DIFFERENTIATION | 10 | 292 | 5.198e-08 | 1.44e-06 |
169 | LEUKOCYTE HOMEOSTASIS | 6 | 60 | 5.344e-08 | 1.471e-06 |
170 | RENAL SYSTEM PROCESS | 7 | 102 | 5.474e-08 | 1.498e-06 |
171 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 12 | 5.926e-08 | 1.612e-06 |
172 | IMMUNE SYSTEM DEVELOPMENT | 13 | 582 | 6.792e-08 | 1.837e-06 |
173 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 32 | 7.336e-08 | 1.94e-06 |
174 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 5 | 32 | 7.336e-08 | 1.94e-06 |
175 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 32 | 7.336e-08 | 1.94e-06 |
176 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 5 | 32 | 7.336e-08 | 1.94e-06 |
177 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 21 | 1672 | 8.288e-08 | 2.179e-06 |
178 | RESPONSE TO COBALT ION | 4 | 13 | 8.538e-08 | 2.232e-06 |
179 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 17 | 1087 | 8.995e-08 | 2.338e-06 |
180 | RESPONSE TO OXYGEN LEVELS | 10 | 311 | 9.373e-08 | 2.423e-06 |
181 | RENAL WATER HOMEOSTASIS | 5 | 34 | 1.008e-07 | 2.568e-06 |
182 | RESPONSE TO CARBOHYDRATE | 8 | 168 | 1.01e-07 | 2.568e-06 |
183 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 8 | 168 | 1.01e-07 | 2.568e-06 |
184 | RESPONSE TO AMINO ACID | 7 | 112 | 1.046e-07 | 2.644e-06 |
185 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 11 | 404 | 1.089e-07 | 2.738e-06 |
186 | GLUCOSE HOMEOSTASIS | 8 | 170 | 1.107e-07 | 2.754e-06 |
187 | CARBOHYDRATE HOMEOSTASIS | 8 | 170 | 1.107e-07 | 2.754e-06 |
188 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 4 | 14 | 1.192e-07 | 2.935e-06 |
189 | REGULATION OF MAP KINASE ACTIVITY | 10 | 319 | 1.187e-07 | 2.935e-06 |
190 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 7 | 121 | 1.779e-07 | 4.356e-06 |
191 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 5 | 38 | 1.8e-07 | 4.385e-06 |
192 | LEUKOCYTE CELL CELL ADHESION | 9 | 255 | 1.978e-07 | 4.794e-06 |
193 | RESPONSE TO DRUG | 11 | 431 | 2.083e-07 | 5.022e-06 |
194 | INOSITOL LIPID MEDIATED SIGNALING | 7 | 124 | 2.104e-07 | 5.046e-06 |
195 | LYMPHOCYTE ACTIVATION | 10 | 342 | 2.262e-07 | 5.398e-06 |
196 | AGING | 9 | 264 | 2.652e-07 | 6.295e-06 |
197 | RESPONSE TO REACTIVE OXYGEN SPECIES | 8 | 191 | 2.706e-07 | 6.392e-06 |
198 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 4 | 17 | 2.813e-07 | 6.61e-06 |
199 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 8 | 193 | 2.93e-07 | 6.852e-06 |
200 | RESPONSE TO OXIDATIVE STRESS | 10 | 352 | 2.95e-07 | 6.863e-06 |
201 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 12 | 552 | 3.091e-07 | 7.155e-06 |
202 | REGULATION OF CELL DIFFERENTIATION | 19 | 1492 | 3.328e-07 | 7.666e-06 |
203 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 10 | 360 | 3.626e-07 | 8.311e-06 |
204 | CELLULAR HOMEOSTASIS | 13 | 676 | 3.793e-07 | 8.652e-06 |
205 | REGULATION OF CYTOKINE PRODUCTION | 12 | 563 | 3.814e-07 | 8.657e-06 |
206 | RESPONSE TO ALKALOID | 7 | 137 | 4.152e-07 | 9.378e-06 |
207 | CELLULAR CHEMICAL HOMEOSTASIS | 12 | 570 | 4.349e-07 | 9.776e-06 |
208 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 11 | 465 | 4.431e-07 | 9.911e-06 |
209 | POSITIVE REGULATION OF MAPK CASCADE | 11 | 470 | 4.924e-07 | 1.096e-05 |
210 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 88 | 5.369e-07 | 1.184e-05 |
211 | LYMPHOCYTE DIFFERENTIATION | 8 | 209 | 5.37e-07 | 1.184e-05 |
212 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 289 | 5.668e-07 | 1.244e-05 |
213 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 8 | 211 | 5.772e-07 | 1.261e-05 |
214 | RESPONSE TO GLUCAGON | 5 | 48 | 5.981e-07 | 1.301e-05 |
215 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 14 | 829 | 6.077e-07 | 1.315e-05 |
216 | REGULATION OF INFLAMMATORY RESPONSE | 9 | 294 | 6.54e-07 | 1.409e-05 |
217 | RESPONSE TO GAMMA RADIATION | 5 | 50 | 7.363e-07 | 1.579e-05 |
218 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 8 | 220 | 7.914e-07 | 1.689e-05 |
219 | CELL DEVELOPMENT | 18 | 1426 | 8.387e-07 | 1.782e-05 |
220 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 5 | 53 | 9.894e-07 | 2.093e-05 |
221 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 23 | 1.031e-06 | 2.17e-05 |
222 | HEMOSTASIS | 9 | 311 | 1.044e-06 | 2.187e-05 |
223 | LIPID PHOSPHORYLATION | 6 | 99 | 1.078e-06 | 2.24e-05 |
224 | REGULATION OF INTRACELLULAR TRANSPORT | 12 | 621 | 1.074e-06 | 2.24e-05 |
225 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 20 | 1784 | 1.14e-06 | 2.358e-05 |
226 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 11 | 514 | 1.185e-06 | 2.439e-05 |
227 | RESPONSE TO RADIATION | 10 | 413 | 1.264e-06 | 2.59e-05 |
228 | LEUKOCYTE ACTIVATION | 10 | 414 | 1.292e-06 | 2.624e-05 |
229 | RESPONSE TO ACID CHEMICAL | 9 | 319 | 1.288e-06 | 2.624e-05 |
230 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 8 | 235 | 1.299e-06 | 2.629e-05 |
231 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 7 | 163 | 1.34e-06 | 2.7e-05 |
232 | POSITIVE REGULATION OF PROTEIN IMPORT | 6 | 104 | 1.441e-06 | 2.89e-05 |
233 | REGULATION OF ORGANELLE ORGANIZATION | 16 | 1178 | 1.521e-06 | 3.037e-05 |
234 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 5 | 58 | 1.559e-06 | 3.1e-05 |
235 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 4 | 26 | 1.727e-06 | 3.419e-05 |
236 | RESPONSE TO METAL ION | 9 | 333 | 1.835e-06 | 3.617e-05 |
237 | RESPONSE TO VIRUS | 8 | 247 | 1.885e-06 | 3.701e-05 |
238 | PROTEIN OLIGOMERIZATION | 10 | 434 | 1.973e-06 | 3.857e-05 |
239 | REGULATION OF MAPK CASCADE | 12 | 660 | 2.025e-06 | 3.926e-05 |
240 | DNA CATABOLIC PROCESS | 4 | 27 | 2.022e-06 | 3.926e-05 |
241 | RESPONSE TO CORTICOSTEROID | 7 | 176 | 2.237e-06 | 4.319e-05 |
242 | PROTEIN HETEROOLIGOMERIZATION | 6 | 113 | 2.342e-06 | 4.504e-05 |
243 | POSITIVE REGULATION OF TRANSPORT | 14 | 936 | 2.549e-06 | 4.882e-05 |
244 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 8 | 258 | 2.607e-06 | 4.971e-05 |
245 | RESPONSE TO KETONE | 7 | 182 | 2.795e-06 | 5.308e-05 |
246 | REGULATION OF PROTEIN IMPORT | 7 | 183 | 2.898e-06 | 5.482e-05 |
247 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 17 | 1395 | 2.947e-06 | 5.551e-05 |
248 | SINGLE ORGANISM CELL ADHESION | 10 | 459 | 3.25e-06 | 6.097e-05 |
249 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 14 | 957 | 3.3e-06 | 6.166e-05 |
250 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 4 | 31 | 3.588e-06 | 6.678e-05 |
251 | RESPONSE TO ALCOHOL | 9 | 362 | 3.631e-06 | 6.732e-05 |
252 | WATER HOMEOSTASIS | 5 | 70 | 3.991e-06 | 7.339e-05 |
253 | REGULATION OF MEMBRANE PERMEABILITY | 5 | 70 | 3.991e-06 | 7.339e-05 |
254 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 9 | 370 | 4.337e-06 | 7.944e-05 |
255 | RESPONSE TO UV | 6 | 126 | 4.411e-06 | 8.017e-05 |
256 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 4.411e-06 | 8.017e-05 |
257 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 4.53e-06 | 8.202e-05 |
258 | REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 481 | 4.917e-06 | 8.867e-05 |
259 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 5.027e-06 | 8.996e-05 |
260 | REGULATION OF LIPID METABOLIC PROCESS | 8 | 282 | 5.027e-06 | 8.996e-05 |
261 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 6 | 129 | 5.054e-06 | 9.01e-05 |
262 | REGULATION OF CELL ACTIVATION | 10 | 484 | 5.193e-06 | 9.223e-05 |
263 | IMMUNE EFFECTOR PROCESS | 10 | 486 | 5.385e-06 | 9.528e-05 |
264 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 381 | 5.497e-06 | 9.688e-05 |
265 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 7 | 203 | 5.745e-06 | 0.0001009 |
266 | B CELL ACTIVATION | 6 | 132 | 5.771e-06 | 0.0001009 |
267 | NEGATIVE REGULATION OF NECROTIC CELL DEATH | 3 | 11 | 6.083e-06 | 0.0001056 |
268 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 11 | 6.083e-06 | 0.0001056 |
269 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 7 | 207 | 6.529e-06 | 0.0001129 |
270 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 36 | 6.631e-06 | 0.0001143 |
271 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 7.148e-06 | 0.0001227 |
272 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 8 | 297 | 7.348e-06 | 0.0001257 |
273 | INSULIN RECEPTOR SIGNALING PATHWAY | 5 | 80 | 7.721e-06 | 0.0001316 |
274 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 3 | 12 | 8.091e-06 | 0.0001369 |
275 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 3 | 12 | 8.091e-06 | 0.0001369 |
276 | JNK CASCADE | 5 | 82 | 8.718e-06 | 0.0001464 |
277 | REGULATION OF PROTEIN MATURATION | 5 | 82 | 8.718e-06 | 0.0001464 |
278 | CELLULAR COMPONENT DISASSEMBLY | 10 | 515 | 8.946e-06 | 0.0001497 |
279 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 218 | 9.157e-06 | 0.0001527 |
280 | REGULATION OF PROTEIN TARGETING | 8 | 307 | 9.352e-06 | 0.0001554 |
281 | RESPONSE TO IONIZING RADIATION | 6 | 145 | 9.898e-06 | 0.0001639 |
282 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 4 | 40 | 1.018e-05 | 0.000168 |
283 | REGULATION OF RESPONSE TO WOUNDING | 9 | 413 | 1.05e-05 | 0.0001721 |
284 | POSITIVE REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 13 | 1.049e-05 | 0.0001721 |
285 | RESPONSE TO TEMPERATURE STIMULUS | 6 | 148 | 1.113e-05 | 0.0001817 |
286 | REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 42 | 1.241e-05 | 0.0002012 |
287 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 4 | 42 | 1.241e-05 | 0.0002012 |
288 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 1.332e-05 | 0.0002152 |
289 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 43 | 1.365e-05 | 0.0002197 |
290 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 7 | 233 | 1.41e-05 | 0.0002263 |
291 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 5 | 92 | 1.531e-05 | 0.0002447 |
292 | REGULATION OF PROTEIN LOCALIZATION | 13 | 950 | 1.594e-05 | 0.000254 |
293 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 437 | 1.646e-05 | 0.0002614 |
294 | APOPTOTIC DNA FRAGMENTATION | 3 | 15 | 1.661e-05 | 0.0002629 |
295 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 11 | 684 | 1.796e-05 | 0.0002832 |
296 | RESPONSE TO ANTIBIOTIC | 4 | 47 | 1.952e-05 | 0.0003069 |
297 | REGULATION OF LIPID KINASE ACTIVITY | 4 | 48 | 2.124e-05 | 0.0003328 |
298 | REGULATION OF AUTOPHAGY | 7 | 249 | 2.164e-05 | 0.0003379 |
299 | PROTEIN COMPLEX BIOGENESIS | 14 | 1132 | 2.225e-05 | 0.0003451 |
300 | PROTEIN COMPLEX ASSEMBLY | 14 | 1132 | 2.225e-05 | 0.0003451 |
301 | REGULATION OF GLUCOSE TRANSPORT | 5 | 100 | 2.295e-05 | 0.0003547 |
302 | CELLULAR RESPONSE TO LIPID | 9 | 457 | 2.342e-05 | 0.0003597 |
303 | CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 7 | 252 | 2.337e-05 | 0.0003597 |
304 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 17 | 2.47e-05 | 0.0003757 |
305 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 3 | 17 | 2.47e-05 | 0.0003757 |
306 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 2.47e-05 | 0.0003757 |
307 | NEGATIVE REGULATION OF NEURON DEATH | 6 | 171 | 2.525e-05 | 0.0003828 |
308 | GLYCEROLIPID METABOLIC PROCESS | 8 | 356 | 2.716e-05 | 0.000409 |
309 | RESPONSE TO NICOTINE | 4 | 51 | 2.707e-05 | 0.000409 |
310 | LEUKOCYTE MIGRATION | 7 | 259 | 2.785e-05 | 0.000418 |
311 | HOMEOSTASIS OF NUMBER OF CELLS | 6 | 175 | 2.877e-05 | 0.0004304 |
312 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 2.957e-05 | 0.000441 |
313 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 3.169e-05 | 0.0004712 |
314 | PHOSPHOLIPID METABOLIC PROCESS | 8 | 364 | 3.181e-05 | 0.0004714 |
315 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 10 | 602 | 3.421e-05 | 0.0005053 |
316 | RESPONSE TO MUSCLE STRETCH | 3 | 19 | 3.503e-05 | 0.000511 |
317 | NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 19 | 3.503e-05 | 0.000511 |
318 | RESPONSE TO HYDROGEN PEROXIDE | 5 | 109 | 3.478e-05 | 0.000511 |
319 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 3 | 19 | 3.503e-05 | 0.000511 |
320 | REGULATION OF MYELOID CELL DIFFERENTIATION | 6 | 183 | 3.696e-05 | 0.0005375 |
321 | CELL CELL ADHESION | 10 | 608 | 3.72e-05 | 0.0005392 |
322 | REGULATION OF MACROPHAGE DIFFERENTIATION | 3 | 20 | 4.112e-05 | 0.0005941 |
323 | INNATE IMMUNE RESPONSE | 10 | 619 | 4.327e-05 | 0.0006234 |
324 | MYELOID CELL DIFFERENTIATION | 6 | 189 | 4.427e-05 | 0.0006357 |
325 | RESPONSE TO STEROID HORMONE | 9 | 497 | 4.506e-05 | 0.0006452 |
326 | B CELL HOMEOSTASIS | 3 | 21 | 4.785e-05 | 0.000683 |
327 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 4.833e-05 | 0.0006877 |
328 | REGULATION OF CELL ADHESION | 10 | 629 | 4.951e-05 | 0.0007024 |
329 | REGULATION OF GLUCOSE IMPORT | 4 | 60 | 5.163e-05 | 0.00073 |
330 | REGULATION OF BODY FLUID LEVELS | 9 | 506 | 5.177e-05 | 0.00073 |
331 | CELLULAR LIPID METABOLIC PROCESS | 12 | 913 | 5.234e-05 | 0.0007357 |
332 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 4 | 61 | 5.511e-05 | 0.0007723 |
333 | RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 3 | 22 | 5.527e-05 | 0.0007723 |
334 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 5 | 122 | 5.964e-05 | 0.0008309 |
335 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 12 | 926 | 5.997e-05 | 0.000833 |
336 | T CELL DIFFERENTIATION | 5 | 123 | 6.2e-05 | 0.0008587 |
337 | RESPONSE TO INSULIN | 6 | 205 | 6.952e-05 | 0.0009599 |
338 | REGULATION OF LEUKOCYTE PROLIFERATION | 6 | 206 | 7.142e-05 | 0.0009832 |
339 | REGULATION OF ANOIKIS | 3 | 24 | 7.229e-05 | 0.0009922 |
340 | REGULATION OF CELL CYCLE | 12 | 949 | 7.586e-05 | 0.001032 |
341 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 10 | 662 | 7.586e-05 | 0.001032 |
342 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 10 | 662 | 7.586e-05 | 0.001032 |
343 | LIPID MODIFICATION | 6 | 210 | 7.942e-05 | 0.001077 |
344 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 7 | 307 | 8.158e-05 | 0.001103 |
345 | APOPTOTIC NUCLEAR CHANGES | 3 | 25 | 8.195e-05 | 0.001105 |
346 | REGULATION OF CELLULAR LOCALIZATION | 14 | 1277 | 8.294e-05 | 0.001115 |
347 | REGULATION OF TRANSPORT | 17 | 1804 | 8.348e-05 | 0.001119 |
348 | NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 4 | 68 | 8.448e-05 | 0.00113 |
349 | POSITIVE REGULATION OF CELL PROLIFERATION | 11 | 814 | 8.722e-05 | 0.001163 |
350 | REGULATION OF HEMOPOIESIS | 7 | 314 | 9.39e-05 | 0.001248 |
351 | POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 70 | 9.463e-05 | 0.001254 |
352 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 5 | 135 | 9.641e-05 | 0.001274 |
353 | REGULATION OF MITOCHONDRION ORGANIZATION | 6 | 218 | 9.757e-05 | 0.001282 |
354 | RESPONSE TO ESTROGEN | 6 | 218 | 9.757e-05 | 0.001282 |
355 | CELLULAR RESPONSE TO RADIATION | 5 | 137 | 0.0001033 | 0.001355 |
356 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 3 | 27 | 0.0001037 | 0.001356 |
357 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 13 | 1142 | 0.0001065 | 0.001389 |
358 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 138 | 0.0001069 | 0.00139 |
359 | NEGATIVE REGULATION OF CELL CYCLE | 8 | 433 | 0.0001074 | 0.001391 |
360 | REGULATION OF CELLULAR RESPONSE TO STRESS | 10 | 691 | 0.0001081 | 0.001397 |
361 | RESPONSE TO COPPER ION | 3 | 28 | 0.0001159 | 0.001494 |
362 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 13 | 1152 | 0.0001163 | 0.001495 |
363 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 4 | 74 | 0.0001176 | 0.001507 |
364 | NEGATIVE REGULATION OF PROTEOLYSIS | 7 | 329 | 0.0001254 | 0.001604 |
365 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 0.0001289 | 0.00163 |
366 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 0.0001289 | 0.00163 |
367 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 3 | 29 | 0.0001289 | 0.00163 |
368 | MUSCLE ADAPTATION | 3 | 29 | 0.0001289 | 0.00163 |
369 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 9 | 573 | 0.0001336 | 0.001685 |
370 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 6 | 232 | 0.0001372 | 0.001725 |
371 | RESPONSE TO ESTRADIOL | 5 | 146 | 0.0001394 | 0.001743 |
372 | CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 146 | 0.0001394 | 0.001743 |
373 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 450 | 0.0001399 | 0.001746 |
374 | TISSUE DEVELOPMENT | 15 | 1518 | 0.0001424 | 0.001771 |
375 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 0.0001429 | 0.001773 |
376 | RESPONSE TO TRANSITION METAL NANOPARTICLE | 5 | 148 | 0.0001486 | 0.001838 |
377 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 10 | 720 | 0.0001513 | 0.001867 |
378 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 15 | 1527 | 0.000152 | 0.001871 |
379 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 152 | 0.0001683 | 0.002066 |
380 | MITOCHONDRION ORGANIZATION | 9 | 594 | 0.000175 | 0.002143 |
381 | GAMETE GENERATION | 9 | 595 | 0.0001772 | 0.002164 |
382 | NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 6 | 245 | 0.0001844 | 0.002246 |
383 | EMBRYO DEVELOPMENT | 11 | 894 | 0.0001988 | 0.002415 |
384 | NEGATIVE REGULATION OF KINASE ACTIVITY | 6 | 250 | 0.0002057 | 0.002493 |
385 | PROTEIN KINASE B SIGNALING | 3 | 34 | 0.0002086 | 0.002514 |
386 | CELLULAR RESPONSE TO ALKALOID | 3 | 34 | 0.0002086 | 0.002514 |
387 | MACROMOLECULAR COMPLEX ASSEMBLY | 14 | 1398 | 0.0002155 | 0.00259 |
388 | NEGATIVE REGULATION OF PROTEIN PROCESSING | 3 | 35 | 0.0002276 | 0.002722 |
389 | NEGATIVE REGULATION OF PROTEIN MATURATION | 3 | 35 | 0.0002276 | 0.002722 |
390 | RESPONSE TO HEAT | 4 | 89 | 0.0002401 | 0.002857 |
391 | B CELL DIFFERENTIATION | 4 | 89 | 0.0002401 | 0.002857 |
392 | CALCIUM MEDIATED SIGNALING | 4 | 90 | 0.0002506 | 0.002975 |
393 | MULTICELLULAR ORGANISM REPRODUCTION | 10 | 768 | 0.0002546 | 0.003015 |
394 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 167 | 0.0002606 | 0.003078 |
395 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 8 | 498 | 0.0002785 | 0.003281 |
396 | REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 4 | 94 | 0.0002961 | 0.003479 |
397 | REGULATION OF CELL CELL ADHESION | 7 | 380 | 0.0003028 | 0.003549 |
398 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 0.0003067 | 0.003586 |
399 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.0003083 | 0.003586 |
400 | REGULATION OF LIPID TRANSPORT | 4 | 95 | 0.0003083 | 0.003586 |
401 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0003147 | 0.003643 |
402 | SPLEEN DEVELOPMENT | 3 | 39 | 0.0003147 | 0.003643 |
403 | EPITHELIUM DEVELOPMENT | 11 | 945 | 0.0003203 | 0.003696 |
404 | FEMALE GAMETE GENERATION | 4 | 96 | 0.0003209 | 0.003696 |
405 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0003394 | 0.00389 |
406 | REGULATION OF ACTIVATED T CELL PROLIFERATION | 3 | 40 | 0.0003394 | 0.00389 |
407 | MITOCHONDRIAL TRANSPORT | 5 | 177 | 0.0003407 | 0.003896 |
408 | MITOTIC SPINDLE ASSEMBLY | 3 | 41 | 0.0003653 | 0.004156 |
409 | MICROTUBULE CYTOSKELETON ORGANIZATION INVOLVED IN MITOSIS | 3 | 41 | 0.0003653 | 0.004156 |
410 | REPRODUCTION | 13 | 1297 | 0.0003725 | 0.004227 |
411 | RESPONSE TO LIGHT STIMULUS | 6 | 280 | 0.0003774 | 0.004273 |
412 | GLAND DEVELOPMENT | 7 | 395 | 0.0003823 | 0.004318 |
413 | REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 4 | 101 | 0.0003894 | 0.004387 |
414 | MUSCLE SYSTEM PROCESS | 6 | 282 | 0.000392 | 0.004406 |
415 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 7 | 397 | 0.0003941 | 0.004418 |
416 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 10 | 823 | 0.0004405 | 0.004927 |
417 | REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 3 | 44 | 0.0004506 | 0.005028 |
418 | LIPID BIOSYNTHETIC PROCESS | 8 | 539 | 0.0004719 | 0.00524 |
419 | PROTEIN DEPHOSPHORYLATION | 5 | 190 | 0.0004713 | 0.00524 |
420 | POSITIVE REGULATION OF INTERLEUKIN 8 PRODUCTION | 3 | 45 | 0.0004816 | 0.005294 |
421 | THYMOCYTE AGGREGATION | 3 | 45 | 0.0004816 | 0.005294 |
422 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 8 | 541 | 0.0004836 | 0.005294 |
423 | LIPID METABOLIC PROCESS | 12 | 1158 | 0.0004798 | 0.005294 |
424 | T CELL DIFFERENTIATION IN THYMUS | 3 | 45 | 0.0004816 | 0.005294 |
425 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 8 | 541 | 0.0004836 | 0.005294 |
426 | REGULATION OF CELL CYCLE ARREST | 4 | 108 | 0.0005021 | 0.005471 |
427 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 108 | 0.0005021 | 0.005471 |
428 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 9 | 689 | 0.0005198 | 0.005651 |
429 | REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 111 | 0.0005568 | 0.006039 |
430 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 8 | 554 | 0.0005654 | 0.006118 |
431 | NEGATIVE REGULATION OF PHOSPHORYLATION | 7 | 422 | 0.000567 | 0.006122 |
432 | REGULATION OF CELL CYCLE PROCESS | 8 | 558 | 0.0005927 | 0.006384 |
433 | OVULATION CYCLE | 4 | 113 | 0.0005956 | 0.0064 |
434 | REGULATION OF TOLL LIKE RECEPTOR SIGNALING PATHWAY | 3 | 49 | 0.0006192 | 0.006639 |
435 | POSITIVE REGULATION OF CELL ACTIVATION | 6 | 311 | 0.0006564 | 0.006998 |
436 | FEMALE SEX DIFFERENTIATION | 4 | 116 | 0.0006573 | 0.006998 |
437 | POSITIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 3 | 50 | 0.0006572 | 0.006998 |
438 | BIOLOGICAL ADHESION | 11 | 1032 | 0.0006719 | 0.007138 |
439 | NEGATIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 3 | 51 | 0.0006966 | 0.007366 |
440 | REGULATION OF INTERLEUKIN 12 PRODUCTION | 3 | 51 | 0.0006966 | 0.007366 |
441 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 4 | 118 | 0.0007008 | 0.007395 |
442 | GERM CELL DEVELOPMENT | 5 | 209 | 0.0007258 | 0.007641 |
443 | REGULATION OF VITAMIN METABOLIC PROCESS | 2 | 12 | 0.0007354 | 0.007676 |
444 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0007374 | 0.007676 |
445 | I KAPPAB PHOSPHORYLATION | 2 | 12 | 0.0007354 | 0.007676 |
446 | POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 52 | 0.0007374 | 0.007676 |
447 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.0007354 | 0.007676 |
448 | REGULATION OF B CELL ACTIVATION | 4 | 121 | 0.00077 | 0.007997 |
449 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 3 | 53 | 0.0007798 | 0.008081 |
450 | SEXUAL REPRODUCTION | 9 | 730 | 0.0007858 | 0.008125 |
451 | REGULATION OF HOMEOSTATIC PROCESS | 7 | 447 | 0.0007958 | 0.008211 |
452 | TUBE MORPHOGENESIS | 6 | 323 | 0.0007995 | 0.00823 |
453 | SYSTEM PROCESS | 15 | 1785 | 0.0008091 | 0.008311 |
454 | NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 3 | 54 | 0.0008236 | 0.008386 |
455 | REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS | 3 | 54 | 0.0008236 | 0.008386 |
456 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 3 | 54 | 0.0008236 | 0.008386 |
457 | B CELL RECEPTOR SIGNALING PATHWAY | 3 | 54 | 0.0008236 | 0.008386 |
458 | HEPATOCYTE APOPTOTIC PROCESS | 2 | 13 | 0.0008672 | 0.008715 |
459 | POSITIVE REGULATION OF ENDOPLASMIC RETICULUM UNFOLDED PROTEIN RESPONSE | 2 | 13 | 0.0008672 | 0.008715 |
460 | REGULATION OF HISTONE PHOSPHORYLATION | 2 | 13 | 0.0008672 | 0.008715 |
461 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.000869 | 0.008715 |
462 | REGULATION OF PROTEIN POLYUBIQUITINATION | 2 | 13 | 0.0008672 | 0.008715 |
463 | PROTEIN AUTOPROCESSING | 2 | 13 | 0.0008672 | 0.008715 |
464 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 2 | 13 | 0.0008672 | 0.008715 |
465 | POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 57 | 0.0009645 | 0.009631 |
466 | APOPTOTIC MITOCHONDRIAL CHANGES | 3 | 57 | 0.0009645 | 0.009631 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | DEATH RECEPTOR BINDING | 8 | 18 | 4.967e-16 | 2.307e-13 |
2 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 10 | 47 | 4.849e-16 | 2.307e-13 |
3 | CYTOKINE RECEPTOR BINDING | 15 | 271 | 1.51e-14 | 4.676e-12 |
4 | KINASE ACTIVITY | 22 | 842 | 2.646e-14 | 4.917e-12 |
5 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 7 | 15 | 2.407e-14 | 4.917e-12 |
6 | ENZYME BINDING | 28 | 1737 | 5.029e-13 | 7.786e-11 |
7 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 22 | 992 | 7.21e-13 | 9.568e-11 |
8 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 9 | 86 | 1.311e-11 | 1.522e-09 |
9 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 15 | 445 | 1.937e-11 | 1.999e-09 |
10 | PROTEIN HETERODIMERIZATION ACTIVITY | 15 | 468 | 3.938e-11 | 3.658e-09 |
11 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 12 | 264 | 8.239e-11 | 6.959e-09 |
12 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 70 | 9.326e-11 | 7.22e-09 |
13 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 43 | 1.118e-10 | 7.992e-09 |
14 | PROTEIN KINASE ACTIVITY | 16 | 640 | 3.145e-10 | 2.087e-08 |
15 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 7 | 51 | 3.933e-10 | 2.436e-08 |
16 | PROTEIN DOMAIN SPECIFIC BINDING | 15 | 624 | 2.1e-09 | 1.219e-07 |
17 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 9 | 184 | 1.199e-08 | 6.188e-07 |
18 | IDENTICAL PROTEIN BINDING | 19 | 1209 | 1.196e-08 | 6.188e-07 |
19 | KINASE REGULATOR ACTIVITY | 9 | 186 | 1.317e-08 | 6.441e-07 |
20 | ADENYL NUCLEOTIDE BINDING | 21 | 1514 | 1.488e-08 | 6.911e-07 |
21 | PROTEIN DIMERIZATION ACTIVITY | 18 | 1149 | 3.345e-08 | 1.48e-06 |
22 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 5 | 30 | 5.219e-08 | 2.204e-06 |
23 | PROTEASE BINDING | 7 | 104 | 6.263e-08 | 2.53e-06 |
24 | ENZYME REGULATOR ACTIVITY | 16 | 959 | 9.667e-08 | 3.742e-06 |
25 | KINASE BINDING | 13 | 606 | 1.085e-07 | 4.031e-06 |
26 | INTERLEUKIN 1 RECEPTOR BINDING | 4 | 16 | 2.157e-07 | 7.706e-06 |
27 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 42 | 3.019e-07 | 1.039e-05 |
28 | MOLECULAR FUNCTION REGULATOR | 18 | 1353 | 3.889e-07 | 1.29e-05 |
29 | RIBONUCLEOTIDE BINDING | 21 | 1860 | 4.987e-07 | 1.598e-05 |
30 | DEATH RECEPTOR ACTIVITY | 4 | 24 | 1.234e-06 | 3.82e-05 |
31 | RECEPTOR BINDING | 18 | 1476 | 1.38e-06 | 4.137e-05 |
32 | PROTEIN COMPLEX BINDING | 14 | 935 | 2.518e-06 | 7.309e-05 |
33 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 3.133e-06 | 8.82e-05 |
34 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 6.083e-06 | 0.0001662 |
35 | PROTEIN KINASE A BINDING | 4 | 42 | 1.241e-05 | 0.0003294 |
36 | HEAT SHOCK PROTEIN BINDING | 5 | 89 | 1.302e-05 | 0.000336 |
37 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 1.661e-05 | 0.0004171 |
38 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 3 | 16 | 2.039e-05 | 0.0004858 |
39 | ENDOPEPTIDASE ACTIVITY | 9 | 448 | 2.003e-05 | 0.0004858 |
40 | PROTEIN HOMODIMERIZATION ACTIVITY | 11 | 722 | 2.954e-05 | 0.0006861 |
41 | ENZYME INHIBITOR ACTIVITY | 8 | 378 | 4.156e-05 | 0.0009418 |
42 | MACROMOLECULAR COMPLEX BINDING | 15 | 1399 | 5.679e-05 | 0.001256 |
43 | CAMP BINDING | 3 | 23 | 6.341e-05 | 0.001339 |
44 | CYSTEINE TYPE ENDOPEPTIDASE INHIBITOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 23 | 6.341e-05 | 0.001339 |
45 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 6.659e-05 | 0.001375 |
46 | GROWTH FACTOR RECEPTOR BINDING | 5 | 129 | 7.775e-05 | 0.00157 |
47 | PEPTIDASE REGULATOR ACTIVITY | 6 | 214 | 8.812e-05 | 0.001742 |
48 | SIGNAL TRANSDUCER ACTIVITY | 16 | 1731 | 0.0001777 | 0.003439 |
49 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 0.0002401 | 0.004552 |
50 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.0002477 | 0.004602 |
51 | PEPTIDASE ACTIVITY | 9 | 663 | 0.0003935 | 0.007167 |
52 | SCAFFOLD PROTEIN BINDING | 3 | 45 | 0.0004816 | 0.008604 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | MEMBRANE MICRODOMAIN | 17 | 288 | 7.131e-17 | 4.165e-14 |
2 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 15 | 237 | 2.078e-15 | 6.068e-13 |
3 | CATALYTIC COMPLEX | 24 | 1038 | 1.892e-14 | 3.684e-12 |
4 | MEMBRANE PROTEIN COMPLEX | 23 | 1020 | 1.313e-13 | 1.918e-11 |
5 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 2.861e-13 | 3.342e-11 |
6 | PROTEIN KINASE COMPLEX | 8 | 90 | 7.259e-10 | 7.065e-08 |
7 | CYTOSOLIC PART | 10 | 223 | 4.013e-09 | 3.348e-07 |
8 | TRANSFERASE COMPLEX | 15 | 703 | 1.046e-08 | 7.637e-07 |
9 | CILIARY BASE | 5 | 23 | 1.255e-08 | 8.145e-07 |
10 | PLASMA MEMBRANE PROTEIN COMPLEX | 13 | 510 | 1.444e-08 | 8.431e-07 |
11 | MEMBRANE REGION | 18 | 1134 | 2.736e-08 | 1.453e-06 |
12 | CD40 RECEPTOR COMPLEX | 3 | 11 | 6.083e-06 | 0.0002733 |
13 | IKAPPAB KINASE COMPLEX | 3 | 11 | 6.083e-06 | 0.0002733 |
14 | RECEPTOR COMPLEX | 8 | 327 | 1.477e-05 | 0.0006161 |
15 | PHOSPHATASE COMPLEX | 4 | 48 | 2.124e-05 | 0.0008271 |
16 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 2.337e-05 | 0.000853 |
17 | MITOCHONDRION | 16 | 1633 | 8.99e-05 | 0.003088 |
18 | PLASMA MEMBRANE RAFT | 4 | 86 | 0.0002104 | 0.006827 |
19 | PLASMA MEMBRANE RECEPTOR COMPLEX | 5 | 175 | 0.0003234 | 0.009443 |
20 | PERINUCLEAR REGION OF CYTOPLASM | 9 | 642 | 0.000311 | 0.009443 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 68 | 89 | 1.227e-176 | 2.172e-174 | |
2 | hsa04620_Toll.like_receptor_signaling_pathway | 22 | 102 | 1.089e-34 | 9.636e-33 | |
3 | hsa04380_Osteoclast_differentiation | 22 | 128 | 2.574e-32 | 1.519e-30 | |
4 | hsa04722_Neurotrophin_signaling_pathway | 21 | 127 | 1.872e-30 | 8.284e-29 | |
5 | hsa04662_B_cell_receptor_signaling_pathway | 18 | 75 | 2.617e-29 | 9.266e-28 | |
6 | hsa04660_T_cell_receptor_signaling_pathway | 19 | 108 | 4.202e-28 | 1.24e-26 | |
7 | hsa04010_MAPK_signaling_pathway | 22 | 268 | 6.065e-25 | 1.534e-23 | |
8 | hsa04062_Chemokine_signaling_pathway | 18 | 189 | 1.338e-21 | 2.959e-20 | |
9 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 16 | 136 | 9.188e-21 | 1.807e-19 | |
10 | hsa04910_Insulin_signaling_pathway | 16 | 138 | 1.171e-20 | 2.073e-19 | |
11 | hsa04370_VEGF_signaling_pathway | 13 | 76 | 3.111e-19 | 5.006e-18 | |
12 | hsa04621_NOD.like_receptor_signaling_pathway | 11 | 59 | 7.395e-17 | 1.091e-15 | |
13 | hsa04914_Progesterone.mediated_oocyte_maturation | 12 | 87 | 1.248e-16 | 1.699e-15 | |
14 | hsa04622_RIG.I.like_receptor_signaling_pathway | 11 | 71 | 6.556e-16 | 8.289e-15 | |
15 | hsa04510_Focal_adhesion | 14 | 200 | 4.851e-15 | 5.725e-14 | |
16 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 2.26e-14 | 2.5e-13 | |
17 | hsa04920_Adipocytokine_signaling_pathway | 10 | 68 | 2.576e-14 | 2.682e-13 | |
18 | hsa04150_mTOR_signaling_pathway | 9 | 52 | 1.148e-13 | 1.129e-12 | |
19 | hsa04115_p53_signaling_pathway | 9 | 69 | 1.69e-12 | 1.575e-11 | |
20 | hsa04630_Jak.STAT_signaling_pathway | 11 | 155 | 4.44e-12 | 3.929e-11 | |
21 | hsa04664_Fc_epsilon_RI_signaling_pathway | 9 | 79 | 5.977e-12 | 5.038e-11 | |
22 | hsa04623_Cytosolic_DNA.sensing_pathway | 8 | 56 | 1.457e-11 | 1.122e-10 | |
23 | hsa04012_ErbB_signaling_pathway | 9 | 87 | 1.458e-11 | 1.122e-10 | |
24 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 9 | 95 | 3.27e-11 | 2.412e-10 | |
25 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 7 | 42 | 9.388e-11 | 6.647e-10 | |
26 | hsa04070_Phosphatidylinositol_signaling_system | 7 | 78 | 8.35e-09 | 5.684e-08 | |
27 | hsa04720_Long.term_potentiation | 6 | 70 | 1.363e-07 | 8.928e-07 | |
28 | hsa04670_Leukocyte_transendothelial_migration | 7 | 117 | 1.412e-07 | 8.928e-07 | |
29 | hsa04114_Oocyte_meiosis | 6 | 114 | 2.466e-06 | 1.505e-05 | |
30 | hsa04810_Regulation_of_actin_cytoskeleton | 7 | 214 | 8.115e-06 | 4.788e-05 | |
31 | hsa04310_Wnt_signaling_pathway | 6 | 151 | 1.248e-05 | 7.124e-05 | |
32 | hsa04020_Calcium_signaling_pathway | 6 | 177 | 3.066e-05 | 0.0001696 | |
33 | hsa04962_Vasopressin.regulated_water_reabsorption | 3 | 44 | 0.0004506 | 0.002417 | |
34 | hsa04742_Taste_transduction | 3 | 52 | 0.0007374 | 0.003839 | |
35 | hsa04340_Hedgehog_signaling_pathway | 3 | 56 | 0.000916 | 0.004632 | |
36 | hsa00562_Inositol_phosphate_metabolism | 3 | 57 | 0.0009645 | 0.004742 | |
37 | hsa04976_Bile_secretion | 3 | 71 | 0.001821 | 0.008713 | |
38 | hsa04971_Gastric_acid_secretion | 3 | 74 | 0.002051 | 0.009552 | |
39 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 4 | 168 | 0.002576 | 0.01169 | |
40 | hsa04640_Hematopoietic_cell_lineage | 3 | 88 | 0.003356 | 0.01485 | |
41 | hsa04970_Salivary_secretion | 3 | 89 | 0.003465 | 0.01496 | |
42 | hsa04540_Gap_junction | 3 | 90 | 0.003576 | 0.01507 | |
43 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.004939 | 0.01987 | |
44 | hsa04916_Melanogenesis | 3 | 101 | 0.004939 | 0.01987 | |
45 | hsa04270_Vascular_smooth_muscle_contraction | 3 | 116 | 0.007246 | 0.0285 | |
46 | hsa04360_Axon_guidance | 3 | 130 | 0.009889 | 0.03805 | |
47 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.01185 | 0.04462 | |
48 | hsa04530_Tight_junction | 2 | 133 | 0.07527 | 0.2776 | |
49 | hsa04740_Olfactory_transduction | 3 | 388 | 0.1455 | 0.5255 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | DGCR5 | hsa-miR-107;hsa-miR-139-5p;hsa-miR-140-5p;hsa-miR-186-5p;hsa-miR-190a-5p;hsa-miR-192-5p;hsa-miR-215-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-29c-3p;hsa-miR-362-3p;hsa-miR-375;hsa-miR-577 | 13 | IL1RAP | Sponge network | 1.383 | 0.01835 | 1.199 | 0.00709 | 0.476 |
2 | RFPL1S |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-362-3p;hsa-miR-3662;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p | 14 | AKT3 | Sponge network | -0.223 | 0.70704 | -0.749 | 0.06936 | 0.466 |
3 | PLAC4 |
hsa-miR-125b-2-3p;hsa-miR-125b-5p;hsa-miR-149-5p;hsa-miR-181a-2-3p;hsa-miR-23a-3p;hsa-miR-23b-3p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-708-3p;hsa-miR-9-3p | 10 | XIAP | Sponge network | -0.563 | 0.27163 | 0.189 | 0.26753 | 0.418 |
4 | FAM66C |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-29a-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 11 | BCL2 | Sponge network | -0.353 | 0.40349 | -1.094 | 0.00317 | 0.407 |
5 | MIAT |
hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-3065-5p;hsa-miR-7-5p | 10 | BCL2 | Sponge network | 0.534 | 0.20962 | -1.094 | 0.00317 | 0.385 |
6 | RFPL1S |
hsa-miR-126-5p;hsa-miR-17-3p;hsa-miR-181b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-215-5p;hsa-miR-26b-5p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-3662 | 10 | IL1R1 | Sponge network | -0.223 | 0.70704 | -0.907 | 0.00472 | 0.367 |
7 | EMX2OS |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-362-3p;hsa-miR-421;hsa-miR-424-5p;hsa-miR-501-3p;hsa-miR-502-3p;hsa-miR-505-3p;hsa-miR-577;hsa-miR-616-5p;hsa-miR-93-5p | 19 | AKT3 | Sponge network | -1.088 | 0.10042 | -0.749 | 0.06936 | 0.354 |
8 | NEAT1 |
hsa-miR-130a-3p;hsa-miR-130b-3p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-224-3p;hsa-miR-224-5p;hsa-miR-301a-3p;hsa-miR-34c-5p;hsa-miR-484;hsa-miR-708-5p;hsa-miR-9-5p | 11 | CFLAR | Sponge network | -0.686 | 0.02293 | 0.072 | 0.73819 | 0.345 |
9 | RFPL1S |
hsa-miR-126-5p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-7-1-3p | 12 | PIK3CA | Sponge network | -0.223 | 0.70704 | 0.181 | 0.37992 | 0.345 |
10 | KCNQ1OT1 | hsa-miR-125b-2-3p;hsa-miR-125b-5p;hsa-miR-149-5p;hsa-miR-181a-2-3p;hsa-miR-23a-3p;hsa-miR-23b-3p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-708-3p;hsa-miR-9-3p | 10 | XIAP | Sponge network | -0.725 | 0.08874 | 0.189 | 0.26753 | 0.342 |
11 | EMX2OS |
hsa-let-7f-1-3p;hsa-miR-107;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-32-5p;hsa-miR-335-3p;hsa-miR-590-3p;hsa-miR-92a-3p;hsa-miR-92b-3p | 10 | PRKAR2B | Sponge network | -1.088 | 0.10042 | -2.312 | 0 | 0.34 |
12 | MIAT |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-501-3p;hsa-miR-502-3p | 11 | AKT3 | Sponge network | 0.534 | 0.20962 | -0.749 | 0.06936 | 0.335 |
13 | MEG3 |
hsa-miR-106b-5p;hsa-miR-107;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-20a-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-3662;hsa-miR-577;hsa-miR-616-5p;hsa-miR-93-5p | 16 | AKT3 | Sponge network | -1.645 | 0.00049 | -0.749 | 0.06936 | 0.312 |
14 | PCA3 |
hsa-miR-103a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-128-3p;hsa-miR-144-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-185-5p;hsa-miR-188-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-224-3p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-324-3p;hsa-miR-330-3p;hsa-miR-424-5p;hsa-miR-532-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-93-5p;hsa-miR-96-5p | 31 | PIK3R1 | Sponge network | -2.778 | 8.0E-5 | -1.094 | 2.0E-5 | 0.309 |
15 | RFPL1S |
hsa-miR-16-2-3p;hsa-miR-181b-5p;hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-29a-5p;hsa-miR-335-3p;hsa-miR-34a-5p;hsa-miR-375;hsa-miR-429;hsa-miR-7-1-3p;hsa-miR-7-5p | 17 | BCL2 | Sponge network | -0.223 | 0.70704 | -1.094 | 0.00317 | 0.308 |
16 | PCA3 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-181b-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-577;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p | 15 | BCL2 | Sponge network | -2.778 | 8.0E-5 | -1.094 | 0.00317 | 0.306 |
17 | PLAC4 |
hsa-miR-205-5p;hsa-miR-20a-3p;hsa-miR-224-3p;hsa-miR-324-5p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-452-3p;hsa-miR-708-3p;hsa-miR-9-3p;hsa-miR-944 | 10 | IRAK3 | Sponge network | -0.563 | 0.27163 | -1.283 | 0.00693 | 0.295 |
18 | AGAP11 |
hsa-let-7f-1-3p;hsa-miR-126-5p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-200b-3p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-501-5p | 11 | PIK3CA | Sponge network | -1.728 | 0.00016 | 0.181 | 0.37992 | 0.282 |
19 | CECR7 | hsa-miR-192-5p;hsa-miR-196b-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-215-5p;hsa-miR-34a-5p;hsa-miR-429;hsa-miR-7-1-3p;hsa-miR-7-5p | 10 | BCL2 | Sponge network | -1.429 | 0.0775 | -1.094 | 0.00317 | 0.276 |
20 | FAM66C |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-5p | 10 | PRKACB | Sponge network | -0.353 | 0.40349 | -2.003 | 0 | 0.273 |
21 | AGAP11 |
hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-2110;hsa-miR-3662;hsa-miR-421;hsa-miR-590-5p;hsa-miR-93-5p | 10 | PRKACB | Sponge network | -1.728 | 0.00016 | -2.003 | 0 | 0.27 |
22 | MALAT1 |
hsa-miR-205-5p;hsa-miR-224-3p;hsa-miR-3200-3p;hsa-miR-335-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-421;hsa-miR-452-3p;hsa-miR-9-3p;hsa-miR-92b-3p;hsa-miR-944 | 11 | IRAK3 | Sponge network | -1.099 | 0.0005 | -1.283 | 0.00693 | 0.259 |
23 | PCA3 |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-146b-5p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-200c-3p;hsa-miR-32-3p;hsa-miR-330-3p;hsa-miR-3662;hsa-miR-577;hsa-miR-590-5p;hsa-miR-616-5p;hsa-miR-93-5p;hsa-miR-96-5p | 18 | PRKACB | Sponge network | -2.778 | 8.0E-5 | -2.003 | 0 | 0.257 |
24 | PART1 |
hsa-miR-146a-5p;hsa-miR-186-5p;hsa-miR-29b-1-5p;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-338-5p;hsa-miR-501-5p;hsa-miR-577;hsa-miR-7-1-3p | 10 | PIK3CA | Sponge network | -2.298 | 0.00168 | 0.181 | 0.37992 | 0.253 |